this pro-inflammatory mesenteric tissue resulted in strong improvement in perineal healing rates.
Background: Anti-TNFα therapy is increasingly used during pregnancy for women with inflammatory bowel disease (IBD). Thus, the knowledge on long-term evolution of exposed children, including response to vaccinations is crucial. A recent study demonstrated an adequate response to two non-live vaccines in 71% and 80% of exposed infants.
1 Our aim was to assess the impact of anti-TNFa exposure in utero for maternal IBD on serologic response to vaccinations in exposed children. Methods: We prospectively included consecutive children (≥12 months of age) born to mothers with IBD (2007 IBD ( -2016 treated with anti-TNFa during pregnancy in three medical centres in Czech Republic. Data on birth, perinatal period, psychomotor development, vaccination, infections, antibiotic use and atopy were collected by treating paediatricians from children's medical files using a predefined questionnaire. Furthermore, a subset of children had a blood sample taken for assessment of immunologic parameters including serologic response to vaccination: (A) non-live vaccines (given within the first year of live): Haemophilus influenza B-HiB, tetanus-TET, diphtheria-DIF, Streptococcus pneumoniae-PNE; (B) live vaccines (given since 15th month of life): parotitis-PAR, rubeola-RUB, morbilli-MOR. Results: Sixty-nine exposed children were included (47.8% girls, median age 35.4 months at last follow-up). Of them, 45 (65.2%) children had a blood sample taken at a median age of 34.8 months. After completion of vaccination protocol, protective antibodies to all non-live vaccines were detected in 63.6% of children while 36.4% of them had inadequate response to at least one non-live vaccine: 23.2% to HiB, 4.5% to TET and 2.4% to PNE. Regarding live-vaccines, protective titres of antibodies were found in 71.4% of vaccinated children and 28.6% had insufficient titres: 25.7% to PAR and 2.9% to each of MOR and RUB. Anti-TNFα levels in cord blood were available for 25 children with blood samples. No significant difference in proportion of protective antibodies to non-live or live vaccines was observed comparing children with a therapeutic (≥3 μg/ml) vs. non-therapeutic cord levels of anti-TNFα (p > 0.05). Conclusions: Two-thirds of children exposed to anti-TNFα in utero had adequate serologic response to non-live and/or live vaccines which is in agreement with findings of a previous study.
1 The highest rate of inadequate response to vaccination was observed in case of haemophilus and parotitis vaccines. A control group of unexposed children is needed to assess the vaccination response in general paediatric population. (Table 1 ). In the older and younger groups, respectively, 51% and 61% of patients reported prior or concomitant exposure to anti-TNFs, 43% and 40% reported concomitant corticosteroids, and 17% and 21% reported a concomitant immunomodulator. Four of the five most commonly reported non-serious AEs were shared by both age groups: fatigue, increased blood pressure, arthralgia and headache ( Table 2 ). The fifth non-serious AE was diarrhoea (older) and exacerbation of UC (younger). Serious AEs were reported by 17% and 12% of patients in the older and younger groups, respectively. Serious AEs more commonly experienced by the older group were events more commonly expected in that age group. Despite experiencing an AE, 76% of patients in each group continued vedolizumab. Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/12/supplement_1/S337/4807540 by guest on 17 March 2019
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Conclusions: AEs reported more frequently in older patients in the post-marketing setting were events more commonly expected in this group. Other AEs were reported at similar frequencies in both age groups. Most patients reporting AEs continued treatment. Limitations of post-marketing safety reports, including incomplete data, voluntary reporting and difficulty establishing a causal relationship between drug and event must be considered when interpreting these results. Background: The goal in the treatment of inflammatory bowel disease (IBD) is to provide mucosal healing and deep remission. Deep remission is defined as complete mucosal healing with clinical remission, and histopathological remission. Studies assessing the efficacy of azathioprine (AZA) in Crohn's disease (CD) and steroid-dependent ulcerative colitis (UC) are limited. This study assess the impact of azathioprine (AZA) on clinical, endoscopic and histopathologic remission rates of IBD, and compares the outcomes of early (0-6 months) and late (6-24 months) initiation of therapy. Methods: In this prospective observational study, patients with UC and CD who have been using AZA for at least 6 months between 2011 and 2016 are evaluated. Throughout the observation period, demographic characteristics, type and localisation of CD, localisation of UC, duration of the disease, operation history, drugs used and pre-AZA laboratory parameters were recorded. Depending on the adverse effects and clinical response, AZA dosages of these patients were adjusted and also recorded. A Mayo score of 0-1 is accepted as remission for UC. For the CD, a CDAI score lower than 150, an SES-CD score lower than 1, or no evidence of mucosal damage and inflammation in the histopathological evaluation is accepted as remission.
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Results: A total of 111 patients, 63 CD, 48 UC, were included in the study. The characteristics of these patients are provided in *Mann-Whitney U test; **chi-square; ***Fisher's exact test.
